Tobrex (Tobramycin) Patent Expiration, LOE Window & CMS Spending

Tobrex (Tobramycin) by Novartis: Off-Patent Uncontested (0 AB Generics), 0 AB generics, $2.1M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorNovartis
FDA Application & PathwayN050555 (NDA)
Exclusivity / Cliff HorizonOff-Patent Uncontested (0 AB Generics)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$2.1M
2024 Medicare Part D Spend$1.3M
2024 Medicaid Spend$808K
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 24.4% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.